COVID‐19 severity from Omicron and Delta SARS‐CoV‐2 variants

The Omicron variant of SARS‐CoV‐2 achieved worldwide dominance in late 2021. Early work suggests that infections caused by the Omicron variant may be less severe than those caused by the Delta variant. We sought to compare clinical outcomes of infections caused by these two strains, confirmed by who...

Full description

Saved in:
Bibliographic Details
Published inInfluenza and other respiratory viruses Vol. 16; no. 5; pp. 832 - 836
Main Authors Wrenn, Jesse O., Pakala, Suman B., Vestal, Grant, Shilts, Meghan H., Brown, Hunter M., Bowen, Sara M., Strickland, Britton A., Williams, Timothy, Mallal, Simon A., Jones, Ian D., Schmitz, Jonathan E., Self, Wesley H., Das, Suman R.
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.09.2022
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The Omicron variant of SARS‐CoV‐2 achieved worldwide dominance in late 2021. Early work suggests that infections caused by the Omicron variant may be less severe than those caused by the Delta variant. We sought to compare clinical outcomes of infections caused by these two strains, confirmed by whole genome sequencing, over a short period of time, from respiratory samples collected from SARS‐CoV‐2 positive patients at a large medical center. We found that infections caused by the Omicron variant caused significantly less morbidity, including admission to the hospital and requirement for oxygen supplementation, and significantly less mortality than those caused by the Delta variant.
Bibliography:Funding information
National Institute of Allergy and Infectious Diseases, Grant/Award Numbers: R21AI142321‐02S1, R21AI149262, R21AI154016, R21AI142321; National Institutes of Health, Grant/Award Numbers: G20RR030956, P30EY08126, P30CA68485, UL1RR024975; National Heart, Lung, and Blood Institute, Grant/Award Numbers: R01HL146401, K23HL148638; Centers for Disease Control and Prevention, Grant/Award Number: 75D3012110094
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Funding information National Institute of Allergy and Infectious Diseases, Grant/Award Numbers: R21AI142321‐02S1, R21AI149262, R21AI154016, R21AI142321; National Institutes of Health, Grant/Award Numbers: G20RR030956, P30EY08126, P30CA68485, UL1RR024975; National Heart, Lung, and Blood Institute, Grant/Award Numbers: R01HL146401, K23HL148638; Centers for Disease Control and Prevention, Grant/Award Number: 75D3012110094
ISSN:1750-2640
1750-2659
DOI:10.1111/irv.12982